James Lee

Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders. Targeting these therapeutic areas with significant unmet medical needs, we apply innovative science to unveil potentially paradigm shifting immunological pathways in the hope to transform the treatment for millions of patients. We consider it our mission to tackle these diseases from their root cause(s) and aim to reach the goal of relieving patients from the disease burden.

Founded in January 2018, xMEMS Labs is reinventing sound with the world’s first solid-state True MEMS speakers for TWS and other personal audio devices. xMEMS has over 100 granted patents worldwide for its technology. The innovative, monolithic transduction architecture implements both actuation and diaphragm in silicon producing the world’s fastest and most precise micro speakers, eliminating spring and suspension recovery of coil speakers. This results in the most accurate time domain music reproduction, unmatched sound clarity, and an elevated sense of space. For more information, visit https://xmems.com.

Cardea Bio is the world’s only mass producer of biocompatible semiconductors, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. In May 2023, Cardea Bio became part of Paragraf, who has revolutionized graphene electronic device manufacturing with its pioneering scalable approach, making it the world's first company to achieve this feat. The acquisition of Cardea Bio and creation of Paragraf USA will enable Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.

TetraMem is developing cutting-edge analog computing solutions for AI applications, offering exceptional performance with ultra-low power consumption.

Chameleon Biosciences, Inc. is a gene therapy startup company based out of Berkeley, CA, United States. Treatments for genetic disorders hold a lot of promise but wont be effective if they trigger an immune response from the very patient its meant to help. Were working on a solution.

WaHa is an early-stage company whose metal-organic framework (MOF) based dehumidifiers atmospheric water generators (AWG) efficiently remove humidity without subcooling the air and create pure water. This dramatically increases HVAC efficiency and reduces opex by 25-90% and HVAC capex by up-to 80%. The initial market is CEA but will scale to the overall HVAC market. This would reduce global HVAC electricity demand by 2%, or 1,900,000 GWh ($250B savings) and global GHG emissions by > 1 gigaton annually. Our AWG systems deliver a reliable quantity of pure, safe drinking water for the lowest energy cost, anywhere in the world, any time of year, under any atmospheric conditions.

Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders. Targeting these therapeutic areas with significant unmet medical needs, we apply innovative science to unveil potentially paradigm shifting immunological pathways in the hope to transform the treatment for millions of patients. We consider it our mission to tackle these diseases from their root cause(s) and aim to reach the goal of relieving patients from the disease burden.

Founded in January 2018, xMEMS Labs is reinventing sound with the world’s first solid-state True MEMS speakers for TWS and other personal audio devices. xMEMS has over 100 granted patents worldwide for its technology. The innovative, monolithic transduction architecture implements both actuation and diaphragm in silicon producing the world’s fastest and most precise micro speakers, eliminating spring and suspension recovery of coil speakers. This results in the most accurate time domain music reproduction, unmatched sound clarity, and an elevated sense of space. For more information, visit https://xmems.com.

Cardea Bio is the world’s only mass producer of biocompatible semiconductors, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. In May 2023, Cardea Bio became part of Paragraf, who has revolutionized graphene electronic device manufacturing with its pioneering scalable approach, making it the world's first company to achieve this feat. The acquisition of Cardea Bio and creation of Paragraf USA will enable Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use.

TetraMem is developing cutting-edge analog computing solutions for AI applications, offering exceptional performance with ultra-low power consumption.

Chameleon Biosciences, Inc. is a gene therapy startup company based out of Berkeley, CA, United States. Treatments for genetic disorders hold a lot of promise but wont be effective if they trigger an immune response from the very patient its meant to help. Were working on a solution.